Gregory Korbel
Chief Operating Officer at Atrin Pharmaceuticals, Inc.
Net worth: 7 178 $ as of 2024-03-30
Gregory Korbel active positions
| Companies | Position | Start | End |
|---|---|---|---|
Atrin Pharmaceuticals, Inc.
 Atrin Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Founded in 2012, Atrin Pharmaceuticals, Inc. is a DNA Damage Response development company that focuses on a pipeline of products resulting from a series of novel conformationally restricted macrocyclic molecules. Part of Aprea Therapeutics, Inc., the private company is based in Doylestown, PA. Atrin Pharmaceuticals was acquired by Aprea Therapeutics, Inc. on May 16, 2022 for $1.33 million. The company's products have the highest known potency for inhibiting ATR and exhibit ATR selectivity with potential broad therapeutic profile. | Chief Operating Officer | - | - |
Career history of Gregory Korbel
Former positions of Gregory Korbel
| Companies | Position | Start | End |
|---|---|---|---|
| APREA THERAPEUTICS, INC. | Chief Operating Officer | 2022-04-30 | 2023-03-30 |
| Corporate Officer/Principal | 2016-06-30 | 2022-04-30 | |
Novira Therapeutics LLC
 Novira Therapeutics LLC Pharmaceuticals: MajorHealth Technology Novira Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company. It focuses on the discovery and development of therapies for the treatment of chronic hepatitis B (CHB) infection. The firm’s novel antiviral drug candidates addresses the limitations of CHB therapies. The company was founded in 2009 by Osvaldo Flores, Ali Munawar and George D. Hartman and is headquartered in Doylestown, PA. | Chief Operating Officer | 2012-07-31 | 2015-11-30 |
| JOHNSON & JOHNSON | Corporate Officer/Principal | - | - |
Training of Gregory Korbel
| Harvard University | Doctorate Degree |
| Vanderbilt University | Undergraduate Degree |
| The Wharton School of the University of Pennsylvania | Masters Business Admin |
Statistics
International
| United States | 8 |
Operational
| Chief Operating Officer | 3 |
| Corporate Officer/Principal | 2 |
| Undergraduate Degree | 1 |
Sectoral
| Health Technology | 5 |
| Consumer Services | 4 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
| Listed companies | 2 |
|---|---|
| JOHNSON & JOHNSON | Health Technology |
| APREA THERAPEUTICS, INC. | Health Technology |
| Private companies | 2 |
|---|---|
Atrin Pharmaceuticals, Inc.
Atrin Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Founded in 2012, Atrin Pharmaceuticals, Inc. is a DNA Damage Response development company that focuses on a pipeline of products resulting from a series of novel conformationally restricted macrocyclic molecules. Part of Aprea Therapeutics, Inc., the private company is based in Doylestown, PA. Atrin Pharmaceuticals was acquired by Aprea Therapeutics, Inc. on May 16, 2022 for $1.33 million. The company's products have the highest known potency for inhibiting ATR and exhibit ATR selectivity with potential broad therapeutic profile. | Health Technology |
Novira Therapeutics LLC
Novira Therapeutics LLC Pharmaceuticals: MajorHealth Technology Novira Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company. It focuses on the discovery and development of therapies for the treatment of chronic hepatitis B (CHB) infection. The firm’s novel antiviral drug candidates addresses the limitations of CHB therapies. The company was founded in 2009 by Osvaldo Flores, Ali Munawar and George D. Hartman and is headquartered in Doylestown, PA. | Health Technology |
- Stock Market
- Insiders
- Gregory Korbel
- Experience
